The PAP called “Key to Life” was approved in China on July 8, 2021 [48], officially providing support that alleviates patients’ out-of-pocket expenses for pembrolizumab (as the first-line monotherapy) for dMMR/MSI-H metastatic or unresectable CRC patients with wild-type KRAS, NRAS and BRAF genes. The gene discussed is NRAS; the disease is colorectal carcinoma.